Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (984)	2/4/2000 12:50:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 4474

(...virus (AAV) to carry the new genes into a patient's body. The viruses do not cause disease in humans) Well it is probably smart for Berger to distance himself from Ad, interesting that in the press release it's suddenly AAV instead of the Wilson hybrid Ad/AAV vector. It's funny, months ago when it was all gloom and doom on the Yahoo board, I kept trying to express that the real story behind Ariad was not the vector, and that the Upenn event should not have any bearing on ARGENT--and yet I think it was a drag on ARIA, even after the toxic was undone. Well, not knowing what I should do, I've simply gone back to the basics on what to own for the AAV--and TGEN's Parker has been very clear about their angle on AAV, so I find myself parked in that one, and going nowhere fast! Oh what I wouldn't give to have had a pile of those warrants still when they touched $6 today! <any thought on is ARIA still a buy at these levels?> Who can say--heck, FBIOX spent the last couple years selling ARIA at lower and lower prices and now we are talking about it being a buy in double digits--dunno, maybe, but you don't want my advice--call the company and see if you can get any hints as to how the hunt for an ARGENT partner is going (having the shareprice way up has to help, dealing with strength these days!).